Liraglutide, leptin and their combined effects on feeding: Additive intake reduction through common intracellular signalling mechanisms

Diabetes, Obesity and Metabolism

Volumn 17, Issue 3, 2015, Pages 285-293

  Kanoski, S E ^a   Ong, Z Y ^b   Fortin, S M ^c   Schlessinger, E S ^b   Grill, H J ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Exendin 4; GLP 1; Obesity; Rat; Synergy; Weight loss

Indexed keywords

LEPTIN; LIRAGLUTIDE; PROTEIN TYROSINE PHOSPHATASE 1B; STAT3 PROTEIN; ANOREXIGENIC AGENT; GLUCAGON LIKE PEPTIDE 1; INCRETIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN THIRD VENTRICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; EX VIVO STUDY; FOOD INTAKE; INTRACELLULAR SIGNALING; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; DRUG COMBINATION; DRUG EFFECTS; EATING; HYPOTHALAMUS; METABOLISM; OBESITY; PROCEDURES; SPRAGUE DAWLEY RAT;

ANIMALS; APPETITE DEPRESSANTS; BODY WEIGHT; DRUG THERAPY, COMBINATION; EATING; GLUCAGON-LIKE PEPTIDE 1; HYPOTHALAMUS; INCRETINS; LEPTIN; LIRAGLUTIDE; MALE; OBESITY; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; RATS; RATS, SPRAGUE-DAWLEY; STAT3 TRANSCRIPTION FACTOR; WEIGHT LOSS;

EID: 84922065431     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12423     Document Type: Article

References (65)

1. Center for Disease Control and Prevention. Overweight and obesity: data and statistics. 2014. Available from URL: http://www.cdc.gov/obesity/data/index.html. Accessed 9 September 2014.
2. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235-241.
3. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood) 2009; 28: w822-831.
4. Jelsing J, Vrang N, Hansen G, Raun K, Tang-Christensen M, Knudsen LB. Liraglutide: short-lived effect on gastric emptying - long lasting effects on body weight. Diabetes Obes Metab 2012; 14: 531-538.
5. Horowitz M, Flint A, Jones KL et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract 2012; 97: 258-266.
6. Hayes MR, Kanoski SE, Alhadeff AL, Grill HJ. Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats. Obesity (Silver Spring) 2011; 19: 1342-1349.
7. Astrup A, Rossner S, Van Gaal L et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606-1616.
8. Raun K, von Voss P, Knudsen LB. Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs. Obesity (Silver Spring) 2007; 15: 1710-1716.
9. Vetter ML, Faulconbridge LF, Webb VL, Wadden TA. Behavioral and pharmacologic therapies for obesity. Nat Rev Endocrinol 2010; 6: 578-588.
10. Greenway FL, Whitehouse MJ, Guttadauria M et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 2009; 17: 30-39.
11. Williams DL, Baskin DG, Schwartz MW. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes 2006; 55: 3387-3393.
12. Bojanowska E, Nowak A. Interactions between leptin and exendin-4, a glucagon-like peptide-1 agonist, in the regulation of food intake in the rat. J Physiol Pharmacol 2007; 58: 349-360.
13. Goldstone AP, Mercer JG, Gunn I et al. Leptin interacts with glucagon-like peptide-1 neurons to reduce food intake and body weight in rodents. FEBS Lett 1997; 415: 134-138.
14. Nowak A, Bojanowska E. Effects of peripheral or central GLP-1 receptor blockade on leptin-induced suppression of appetite. J Physiol Pharmacol 2008; 59: 501-510.
15. Zhao S, Kanoski SE, Yan J, Grill HJ, Hayes MR. Hindbrain leptin and glucagon-like-peptide-1 receptor signaling interact to suppress food intake in an additive manner. Int J Obes 2012; 36: 1522-1528.
16. Goldstone AP, Morgan I, Mercer JG et al. Effect of leptin on hypothalamic GLP-1 peptide and brain-stem pre-proglucagon mRNA. Biochem Biophys Res Commun 2000; 269: 331-335.
17. Sanz C, Vazquez P, Navas MA, Alvarez E, Blazquez E. Leptin but not neuropeptide Y up-regulated glucagon-like peptide 1 receptor expression in GT1-7 cells and rat hypothalamic slices. Metabolism 2008; 57: 40-48.
18. Scott KA, Moran TH. The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. Am J Physiol Regul Integr Comp Physiol 2007; 293: R983-987.
19. Williams DL, Baskin DG, Schwartz MW. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 2009; 150: 1680-1687.
20. Mietlicki-Baase EG, Ortinski PI, Rupprecht LE et al. The food intake-suppressive effects of glucagon-like peptide-1 receptor signaling in the ventral tegmental area are mediated by AMPA/kainate receptors. Am J Physiol Endocrinol Metab 2013; 305: E1367-1374.
21. Hsu TM, Hahn JD, Konanur VR, Lam A, Kanoski SE. Hippocampal GLP-1 receptors influence food intake, meal size, and effort-based responding for food through volume transmission. Neuropsychopharmacology 2015; 40: 327-337.
22. Eckel LA, Langhans W, Kahler A, Campfield LA, Smith FJ, Geary N. Chronic administration of OB protein decreases food intake by selectively reducing meal size in female rats. Am J Physiol 1998; 275: R186-193.
23. Kahler A, Geary N, Eckel LA, Campfield LA, Smith FJ, Langhans W. Chronic administration of OB protein decreases food intake by selectively reducing meal size in male rats. Am J Physiol 1998; 275: R180-185.
24. Ho A, Chin A. Circadian feeding and drinking patterns of genetically obese mice fed solid chow diet. Physiol Behav 1988; 43: 651-656.
25. Kanoski SE, Zhao S, Guarnieri DJ et al. Endogenous leptin receptor signaling in the medial nucleus tractus solitarius affects meal size and potentiates intestinal satiation signals. Am J Physiol Endocrinol Metab 2012; 303: E496-503.
26. Zorrilla EP, Inoue K, Valdez GR, Tabarin A, Koob GF. Leptin and post-prandial satiety: acute central leptin more potently reduces meal frequency than meal size in the rat. Psychopharmacology (Berl) 2005; 177: 324-335.
27. Myers MG Jr. Leptin receptor signaling and the regulation of mammalian physiology. Recent Prog Horm Res 2004; 59: 287-304.
28. Shirazi R, Palsdottir V, Collander J et al. Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6. Proc Natl Acad Sci U S A 2013; 110: 16199-16204.
29. Ritter RC, Slusser PG, Stone S. Glucoreceptors controlling feeding and blood glucose: location in the hindbrain. Science 1981; 213: 451-452.
30. Kanoski SE, Rupprecht LE, Fortin SM, De Jonghe BC, Hayes MR. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology 2012; 62: 1916-1927.
31. Cusin I, Rohner-Jeanrenaud F, Stricker-Krongrad A, Jeanrenaud B. The weight-reducing effect of an intracerebroventricular bolus injection of leptin in genetically obese fa/fa rats. Reduced sensitivity compared with lean animals. Diabetes 1996; 45: 1446-1450.
32. Kanoski SE, Fortin SM, Ricks KM, Grill HJ. Ghrelin signaling in the ventral hippocampus stimulates learned and motivational aspects of feeding via PI3K-Akt signaling. Biol Psychiatry 2013; 73: 915-923.
33. Hayes MR, Leichner TM, Zhao S et al. Intracellular signals mediating the food intake-suppressive effects of hindbrain glucagon-like peptide-1 receptor activation. Cell Metab 2011; 13: 320-330.
34. Cakir B, Kasimay O, Devseren E, Yegen BC. Leptin inhibits gastric emptying in rats: role of CCK receptors and vagal afferent fibers. Physiol Res 2007; 56: 315-322.
35. Flynn MC, Scott TR, Pritchard TC, Plata-Salaman CR. Mode of action of OB protein (leptin) on feeding. Am J Physiol 1998; 275: R174-179.
36. Castonguay TW, Kaiser LL, Stern JS. Meal pattern analysis: artifacts, assumptions and implications. Brain Res Bull 1986; 17: 439-443.
37. Demaria-Pesce VH, Nicolaidis S. Mathematical determination of feeding patterns and its consequence on correlational studies. Physiol Behav 1998; 65: 157-170.
38. Kissileff HR. Free feeding in normal and "recovered lateral" rats monitored by a pellet-detecting eatometer. Physiol Behav 1970; 5: 163-173.
39. Clifton PG. Meal patterning in rodents: psychopharmacological and neuroanatomical studies. Neurosci Biobehav Rev 2000; 24: 213-222.
40. Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 2011; 152: 3103-3112.
41. Cummings BP, Stanhope KL, Graham JL et al. Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats. Diabetes 2010; 59: 2653-2661.
42. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007; 56: 8-15.
43. Dossat AM, Lilly N, Kay K, Williams DL. Glucagon-like peptide 1 receptors in nucleus accumbens affect food intake. J Neurosci 2011; 31: 14453-14457.
44. Ruttimann EB, Arnold M, Hillebrand JJ, Geary N, Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 2009; 150: 1174-1181.
45. Sisley S, Gutierrez-Aguilar R, Scott M, D'Alessio DA, Sandoval DA, Seeley RJ. Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. J Clin Invest 2014; 124: 2456-2463.
46. Kinzig KP, D'Alessio DA, Seeley RJ. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci 2002; 22: 10470-10476.
47. Elmquist JK, Bjorbaek C, Ahima RS, Flier JS, Saper CB. Distributions of leptin receptor mRNA isoforms in the rat brain. J Comp Neurol 1998; 395: 535-547.
48. Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 1999; 403: 261-280.
49. Myers MG, Cowley MA, Munzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 2008; 70: 537-556.
50. Wu Y, Yu Y, Szabo A, Han M, Huang XF. Central inflammation and leptin resistance are attenuated by ginsenoside Rb1 treatment in obese mice fed a high-fat diet. PLoS One 2014; 9: e92618.
51. Myers MP, Andersen JN, Cheng A et al. TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J Biol Chem 2001; 276: 47771-47774.
52. Zabolotny JM, Bence-Hanulec KK, Stricker-Krongrad A et al. PTP1B regulates leptin signal transduction in vivo. Dev Cell 2002; 2: 489-495.
53. Bence KK, Delibegovic M, Xue B et al. Neuronal PTP1B regulates body weight, adiposity and leptin action. Nat Med 2006; 12: 917-924.
54. Morrison CD, White CL, Wang Z et al. Increased hypothalamic protein tyrosine phosphatase 1B contributes to leptin resistance with age. Endocrinology 2007; 148: 433-440.
55. Remage-Healey L. Frank Beach Award Winner: steroids as neuromodulators of brain circuits and behavior. Horm Behav 2014; 66: 552-560.
56. Van Dijk G, Thiele TE, Donahey JC et al. Central infusions of leptin and GLP-1-(7-36) amide differentially stimulate c-FLI in the rat brain. Am J Physiol 1996; 271: R1096-1100.
57. Cowley MA, Smart JL, Rubinstein M et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 2001; 411: 480-484.
58. Secher A, Jelsing J, Baquero AF et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 2014; 124: 4473-4488.
59. Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology 2012; 153: 647-658.
60. Hommel JD, Trinko R, Sears RM et al. Leptin receptor signaling in midbrain dopamine neurons regulates feeding. Neuron 2006; 51: 801-810.
61. Kanoski SE, Hayes MR, Greenwald HS et al. Hippocampal leptin signaling reduces food intake and modulates food-related memory processing. Neuropsychopharmacology 2011; 36: 1859-1870.
62. Nonogaki K, Hazama M, Satoh N. Liraglutide suppresses obesity and hyperglycemia associated with increases in hepatic fibroblast growth factor 21 production in KKAy mice. Biomed Res Int 2014; 2014: 751930.
63. Yang M, Zhang L, Wang C et al. Liraglutide increases FGF-21 activity and insulin sensitivity in high fat diet and adiponectin knockdown induced insulin resistance. PLoS One 2012; 7: e48392.
64. Muller TD, Sullivan LM, Habegger K et al. Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J Pept Sci 2012; 18: 383-393.
65. Sarruf DA, Thaler JP, Morton GJ et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 2010; 59: 1817-1824.